22157.jpg
Global Pain Therapeutics Market to 2029 - Featuring Abbott Laboratories, AstraZeneca and GlaxoSmithKline Among Others
March 28, 2022 07:33 ET | Research and Markets
Dublin, March 28, 2022 (GLOBE NEWSWIRE) -- The "Pain Therapeutics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts,...
Global Cancer Pain Market
Insights on the Cancer Pain Global Market to 2030 - Rising Healthcare Expenditure and Government Support Worldwide are Driving Growth
March 09, 2022 04:58 ET | Research and Markets
Dublin, March 09, 2022 (GLOBE NEWSWIRE) -- The "Global Cancer Pain Market, By Drug Type, By Disease Indication, Estimation & Forecast, 2017 - 2030" report has been added to...
Elite Pharmaceuticals, Inc. Logo
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2013, FQ4/13 Revenues Highest in Corporate History
June 21, 2013 13:44 ET | Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., June 21, 2013 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. (OTCBB:ELTP), a specialty pharmaceutical company dedicated to developing and commercializing oral abuse-resistant...
Elite Pharmaceuticals, Inc. Logo
Elite Pharmaceuticals, Inc. Announces 2013 Fiscal Year End Conference Call on Monday, June 24, 2013
June 19, 2013 08:00 ET | Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., June 19, 2013 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. (OTCBB:ELTP), a specialty pharmaceutical company dedicated to developing and commercializing oral sustained and...
Elite Pharmaceuticals, Inc. Logo
Elite Pharmaceuticals Announces First Shipment of Generic Hydromorphone Product
March 13, 2012 08:30 ET | Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., March 13, 2012 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite") (OTCBB:ELTP) announced today the initial shipment of hydromorphone hydrochloride 8 mg tablets, the generic...